Recombinant Interleukin-11

Neuroblastoma

Fred Hutchinson Cancer CenterPhase 2Dormant

B

57/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 42/ 100
Competitive Position: 81/ 100

Competitive context

63 Active assets in the Neuroblastoma cohort.

Asset / Sponsor	Phase	Rating
Irinotecan National Cancer Institute (NCI)	Phase 2	BB
FILGRASTIM M.D. Anderson Cancer Center	Phase 4	BB
ETOPOSIDE M.D. Anderson Cancer Center	Phase 2/3	BB
Eloxatin National Cancer Institute (NCI)	Phase 2	BB
Cyclophosphamide Robbie Majzner	Phase 2	BB

View all 50 →

Same molecule, other indications

Recombinant Interleukin-11 is also rated in:

testicular germ cell tumorDormant

B

Indicative ·

57 / 100

gestational trophoblastic neoplasmDormant

B

Indicative ·

57 / 100

kidney cancerDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.